Men – LOS ANGELES, U.S. oncologists say a new class of targeted anti-cancer drugs shows promise in prolonging the lives of patients with recurrent prostate cancer. The research by scientists at Cedars-Sinai Medical Center in Los Angeles show a molecular targeted compound called pertuzumab blocks the human epidermal growth factor receptor family by bi
Not a member? Sign-up today!
About Propeller | Frequently Asked Questions | Help
© 2003-2008 Propeller. All Rights Reserved. Terms of Use | Privacy Policy
0)
Vote